SEC Form 4 · accession 0001140361-15-025873

BioPharmX Corp · BPMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 25, 2015

Accepted (ET)

Jun 29, 2015 · 7:58 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001504167

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Jun 25, 2015	C	13,839	—	A	218,707	I	By Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F2,F3	—	Jun 25, 2015	C	13,514	D	—	—	Common Stock	13,514	0	I

F1Includes 325 shares of Common Stock received by Mr. Morlock in payment for accrued interest on his Series A investment (the "Common Stock Interest Payment"), pursuant to the terms of that certain Amended and Restated Designations, Preferences and Rights of Series A Preferred Stock dated May 11, 2015 and in connection with the Issuer's public offering on June 25, 2015 (the "Public Offering"). The Common Stock Interest Payment was approved by the Issuer's board of directors on June 12, 2015 and applied to all holders of the Issuer's Series A Convertible Preferred Stock.
F2Each share of Series A Convertible Preferred Stock automatically converted into one (1) share of Common Stock upon the completion of the Issuer's Public Offering and had no expiration date.
F3Mr. Morlock is a co-trustee and co-beneficiary of the Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03.